Aberrant oscillatory activity in Neurofibromatosis Type 1: An EEG study of resting state and working memory
Aberrant oscillatory activity in Neurofibromatosis Type 1: An EEG study of resting state and working memory
复制标题
1 型神经纤维瘤病的异常振荡活动：静息状态和工作记忆的脑电图研究
DOI：
10.1101/2022.08.24.22279165
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Booth S
中科院分区：
文献类型：
--
作者：
Booth S
背景1型神经纤维瘤病（NF 1）是一种遗传性神经发育障碍，常伴有认知功能障碍。尽管神经振荡在神经典型人群中的功能作用已经得到了很好的探索，但只有有限数量的研究调查了NF 1人群中的振荡活动。（N= 16;平均年龄：13.03岁;女性：n= 7）至年龄/性别匹配的典型发育对照组（N= 16;平均年龄：13.34岁;女性：n= 7）使用脑电图测量在休息和工作记忆任务performance.ResultsRelative相对于典型的发展中国家的儿童，NF 1组显示较高的静息状态慢波功率和较低的峰值α频率。此外，在工作记忆任务执行期间，在NF 1组中观察到更高的θ功率和额顶叶θ相位一致性，但当控制基线（静息状态）activity.ConclusionsOverall时，这些差异消失，结果表明NF 1的特征是异常的静息状态振荡活动，可能导致该人群经历的认知障碍。试验registrationClinicalTrials.gov，NCT 03310996（首次发布：2017年10月16日）。
BackgroundNeurofibromatosis type 1 (NF1) is a genetic neurodevelopmental disorder commonly associated with impaired cognitive function. Despite the well-explored functional roles of neural oscillations in neurotypical populations, only a limited number of studies have investigated oscillatory activity in the NF1 population.MethodsWe compared oscillatory spectral power and theta phase coherence in a paediatric sample with NF1 (N= 16; mean age: 13.03 years; female:n= 7) to an age/sex-matched typically developing control group (N= 16; mean age: 13.34 years; female:n= 7) using electroencephalography measured during rest and during working memory task performance.ResultsRelative to typically developing children, the NF1 group displayed higher resting state slow wave power and a lower peak alpha frequency. Moreover, higher theta power and frontoparietal theta phase coherence were observed in the NF1 group during working memory task performance, but these differences disappeared when controlling for baseline (resting state) activity.ConclusionsOverall, results suggest that NF1 is characterised by aberrant resting state oscillatory activity that may contribute towards the cognitive impairments experienced in this population.Trial registrationClinicalTrials.gov, NCT03310996 (first posted: October 16, 2017).